Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z7ZM
|
|||
| Former ID |
DCL000953
|
|||
| Drug Name |
Rhucin
|
|||
| Synonyms |
sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4; ICD-9: 302.72, 607.84] | Approved | [1], [2] | |
| Hereditary angioedema [ICD-11: 4A00.14; ICD-9: 277.6] | Approved | [3], [4] | ||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H30N6O4S
|
|||
| Canonical SMILES |
CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
|
|||
| InChI |
1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
|
|||
| InChIKey |
BNRNXUUZRGQAQC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 139755-83-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9468, 585744, 832888, 4075716, 4368414, 4980084, 7980598, 8153203, 11342069, 11362252, 11364449, 11367011, 11369573, 11373023, 11374191, 11377735, 11485511, 11487654, 11489464, 11491707, 11492401, 11495369, 11528697, 14834479, 14883184, 26612617, 26680877, 26748898, 26748899, 29215463, 29224269, 46393303, 46393579, 46394222, 46508371, 46514731, 47810856, 48259349, 48416538, 50085897, 50416042, 53786977, 56313704, 56322606, 57322656, 61212546, 81040866, 85248200, 85788522, 89736128
|
|||
| ChEBI ID |
CHEBI:9139
|
|||
| ADReCS Drug ID | BADD_D00327 ; BADD_D02018 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C1 esterase inhibitor (SERPING1) | Target Info | Modulator | [3], [4] |
| Phosphodiesterase 5A (PDE5A) | Target Info | Inhibitor | [5], [6], [7], [8] | |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4743). | |||
| REF 2 | Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007 Sep;12(3):367-88. | |||
| REF 3 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | |||
| REF 4 | Recombinant human c1 inhibitor (conestat alfa): in the treatment of angioedema attacks in hereditary angioedema. BioDrugs. 2012 Oct 1;26(5):315-23. | |||
| REF 5 | cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91. | |||
| REF 6 | Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology. 2002 Sep;60(2 Suppl 2):49-57. | |||
| REF 7 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||
| REF 8 | Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res. 2002 Dec;14(6):466-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.